Thursday, October 8, 2015
The EMA has recommended granting a marketing authorization, following Accelerated Assessment, for Praxbind (idarucizumab) as a specific antidote to the anticoagulant medicine Pradaxa (dabigatran etexilate), when rapid reversal of its effect is required. Praxbind is to be used when a patient taking Pradaxa needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs.
Venn Life Sciences, a European CRO, has entered into an agreement to acquire the entire issued share capital of Kinesis Pharma, a Netherlands-based provider of specialist consultancy services around the chemical-pharmaceutical, nonclinical and early clinical development of drug products, for a total maximum consideration of up to $7.3 million (€6.5 million).
A new report says the difference in cancer survival rates between England and rest of Europe has stood at about 10% for the past 20 years, and closing that divide would add about £117 million ($180 million) a year to the U.K. economy.
Quotient Clinical, a translational pharmaceutics company, has expanded its data sciences services in response to increasing customer demand, doubling the footprint of its facilities in Edinburgh and Nottingham, as well as increasing its specialist headcount and appointing a new vice president.
Mytrus, a technology and services company working in clinical trials, has announced its software platform for electronic informed consent has received approval for use by Britain’s National Health Service (NHS). It is the first time e-Consent technology will be used in a trial in England.